Neuropathy Treatment Bloomfield Hills 2026 | Balance Foot & Ankle

What Is Peripheral Neuropathy? Pathophysiology Explained

Peripheral neuropathy is injury or dysfunction of the peripheral nervous system — the network of nerves outside the brain and spinal cord that controls sensation, movement, and autonomic function in the feet and legs. The defining characteristic of the most common form, length-dependent peripheral neuropathy, is that the longest nerve fibers are damaged first. Because the nerves innervating the toes and feet are the longest in the body, symptoms begin distally and progress proximally — producing the characteristic stocking-glove distribution (feet and hands affected before more proximal regions).

At the cellular level, neuropathy involves one or more of three pathological mechanisms:

• Axonal degeneration: The nerve axon itself degenerates (common in diabetic and toxic neuropathies). Wallerian degeneration occurs distal to the site of injury. Recovery is slow and often incomplete because axonal regeneration proceeds at only 1–4 mm/day.
• Demyelination: The myelin sheath surrounding the axon is damaged, slowing nerve conduction velocity. Seen in inflammatory neuropathies (CIDP, GBS) and some hereditary forms. Remyelination and recovery can be faster than axonal types.
• Microvascular injury: In diabetic peripheral neuropathy, hyperglycemia causes endoneurial hypoxia through thickening of endoneurial capillary basement membranes, increased oxidative stress (advanced glycation end-products), and impaired nerve growth factor signaling — ultimately starving nerve fibers of oxygen and nutrients.

Small Fiber vs. Large Fiber Neuropathy

This distinction is clinically important because it determines presentation, diagnosis method, and treatment approach:

• Small fiber neuropathy (SFN): Affects unmyelinated C fibers and thinly myelinated A-delta fibers. These carry pain and temperature sensation. Patients experience burning, stabbing, electric-shock pain, allodynia (pain from non-painful stimuli like bed sheets), and heat/cold dysesthesias. Standard nerve conduction studies (NCS) are NORMAL — SFN requires skin punch biopsy (reduced intraepidermal nerve fiber density) or quantitative sensory testing (QST) for diagnosis. Autonomic symptoms (dry feet, reduced sweating) common. This is the form most commonly seen early in diabetic neuropathy.
• Large fiber neuropathy: Affects myelinated A-alpha and A-beta fibers carrying proprioception, vibration, and motor signals. Loss of protective sensation (10g monofilament), reduced vibration (128 Hz tuning fork), absent ankle reflexes, ataxia (positive Romberg), and weakness. NCS detects large fiber dysfunction — reduced amplitudes and slowed conduction velocities. This pattern creates the greatest fall risk and ulcer risk.

Most patients with established diabetic peripheral neuropathy have mixed small and large fiber involvement.

Causes of Peripheral Neuropathy

The differential is extensive; a systematic approach prevents missing treatable causes:

• Diabetes mellitus (most common — ~50%): Diabetic peripheral neuropathy (DPN) correlates strongly with duration of diabetes and glycemic control. The DCCT trial demonstrated that intensive insulin therapy reduces neuropathy progression by 60% in Type 1 DM. Roughly 50% of all diabetics develop neuropathy within 25 years of diagnosis.
• Idiopathic (~25%): No identifiable cause found after thorough workup. Often slowly progressive, predominantly sensory. Patients over 60 are disproportionately affected. Metabolic syndrome may be an underappreciated contributor.
• Vitamin B12 deficiency: B12 is essential for myelin synthesis. Deficiency produces a predominantly posterior-column and large-fiber pattern. Common causes: pernicious anemia, metformin use (metformin blocks B12 absorption — critically important in diabetics), veganism, gastric bypass surgery, proton pump inhibitor long-term use. Highly treatable if caught before axonal loss occurs.
• Thyroid disease (hypothyroidism): Produces a symmetrical sensorimotor neuropathy through myxedematous infiltration of nerve sheaths. TSH is a mandatory first-line lab in any neuropathy workup. Resolves with thyroid hormone replacement.
• Alcohol-related neuropathy: Direct toxic effect of ethanol on peripheral nerves, compounded by nutritional deficiencies (B1/thiamine, B6, B12). Predominantly axonal and sensory; painful. Presents identically to DPN.
• Chemotherapy-induced peripheral neuropathy (CIPN): Platinum agents (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), and vinca alkaloids cause dose-dependent, length-dependent neuropathy. Oxaliplatin causes acute cold-triggered dysesthesias in addition to chronic neuropathy. Often partially reversible after treatment completion.
• HIV-associated neuropathy: Distal sensory polyneuropathy is the most common neurological complication of HIV infection, affecting up to 35% of patients — from direct viral neurotoxicity, immune dysregulation, and antiretroviral drug toxicity.
• Other metabolic causes: Chronic kidney disease (uremic neuropathy), liver disease, paraproteinemia (MGUS, multiple myeloma), sarcoidosis, vasculitis, Lyme disease.

Signs and Symptoms

The clinical presentation depends on which fiber types are affected and the disease stage:

• Burning, stinging, or electric-shock sensations in the feet (often worse at night)
• Numbness and loss of sensation — inability to feel heat, cold, or pain
• Tingling or “pins and needles” (paresthesias)
• Allodynia — pain from light touch (bed sheets, sock seams)
• Balance problems and falls (loss of proprioception)
• Muscle weakness in the feet and ankles (intrinsic muscle atrophy — “intrinsic minus” foot)
• Changes in foot shape — hammer toes, clawing of toes from intrinsic muscle loss
• Dry, cracked feet and skin (autonomic dysfunction causing anhidrosis)
• Painless wounds or blisters that go unnoticed (loss of protective sensation)

Diagnosis: Clinical Exam and Testing

Neuropathy diagnosis begins at the bedside. Our evaluation includes:

• Semmes-Weinstein 10g monofilament: Tests large fiber protective sensation at 10 plantar sites. Inability to detect the monofilament at 4 or more sites indicates clinically significant loss of protective sensation and ulcer risk.
• 128 Hz tuning fork: Vibration perception at the hallux and medial malleolus. Diminished vibration is an early large fiber finding.
• Ankle reflexes: Absent Achilles reflexes are a reliable marker of peripheral neuropathy.
• Pinprick and temperature testing: Assesses small fiber function.
• Nerve conduction study (NCS) and electromyography (EMG): Ordered when diagnosis is uncertain, to characterize axonal vs. demyelinating pattern, and to grade severity. Cannot detect pure small fiber neuropathy.
• Laboratory workup: Fasting glucose and HbA1c, B12, TSH, CBC, CMP, SPEP (if paraproteinemia suspected), ESR, ANA if vasculitic pattern.
• Skin punch biopsy: Gold standard for small fiber neuropathy — intraepidermal nerve fiber density (IENFD) quantified against normative data.

Neuropathy vs. Similar Conditions

• Tarsal tunnel syndrome: Compression of the posterior tibial nerve behind the medial malleolus produces burning, tingling, and numbness in the plantar foot and toes — mimicking neuropathy exactly. Key distinction: tarsal tunnel is unilateral, Tinel’s sign over the tarsal tunnel is positive, and NCS localizes the lesion to the tunnel. Neuropathy is bilateral and symmetric.
• Lumbar radiculopathy (L4-S1): Herniated disc or spinal stenosis compresses nerve roots, causing pain and numbness in a dermatomal (not stocking) distribution. Associated with back pain, unilateral symptoms, and positive straight-leg raise. MRI lumbar spine is diagnostic.
• Raynaud’s phenomenon: Episodic vasospasm causing color changes (white-blue-red), cold sensitivity, and numbness in the toes — triggered by cold or stress. Bilateral but episodic, not constant. No sensory loss between episodes.
• Complex regional pain syndrome (CRPS): Allodynia and burning pain following trauma, but with characteristic autonomic changes (skin color changes, sweating asymmetry, hair/nail changes) and typically unilateral distribution. Budapest criteria used for diagnosis.

Treatment Options

Step 1: Treat the Underlying Cause

This is the most powerful intervention and is often overlooked in favor of symptom management. Tight glycemic control (HbA1c <7%) is associated with reduced neuropathy progression in both Type 1 and Type 2 DM. B12 repletion should be aggressive — 1000 mcg IM monthly until levels normalize in pernicious anemia; oral high-dose B12 for other deficiency states. Thyroid replacement resolves hypothyroid neuropathy. Alcohol cessation stops progression of alcohol neuropathy.

Step 2: Nutritional Supplements with Evidence Base

• Alpha lipoic acid (ALA): 600 mg daily (oral) or IV formulations. ALA is a potent antioxidant that reduces oxidative stress in endoneurial capillaries. The SYDNEY II trial demonstrated significant improvement in neuropathic symptom score with 600 mg/day vs. placebo over 5 weeks. Best evidence base of any supplement in DPN.
• B-complex vitamins: B1 (benfotiamine — fat-soluble form with superior bioavailability), B6, B12. Address nutritional deficiency components and support myelin synthesis. Avoid excessive B6 (pyridoxine) — doses above 200 mg/day paradoxically worsen neuropathy.
• Vitamin D: Deficiency is associated with increased neuropathy severity; supplementation to achieve 25-OH-D above 40 ng/mL is reasonable given low risk and high prevalence of deficiency.
• Acetyl-L-carnitine: May support axonal regeneration and improve nerve conduction; limited but supportive trial data.

Step 3: Symptomatic Pharmacotherapy

• Gabapentin (Neurontin): Alpha-2-delta ligand; reduces calcium-channel-mediated central sensitization. Start 100–300 mg at bedtime, titrate to 900–3600 mg/day in divided doses. Side effects: sedation, dizziness, edema. Requires dose adjustment in CKD.
• Pregabalin (Lyrica): More predictable pharmacokinetics than gabapentin; FDA-approved for DPN. 75–300 mg twice daily. Faster onset than gabapentin. Schedule V controlled substance.
• Duloxetine (Cymbalta): SNRI; FDA-approved for DPN. 60–120 mg daily. Particularly useful in patients with comorbid depression. Monitor blood pressure.
• Tricyclic antidepressants (amitriptyline, nortriptyline): Effective for neuropathic pain but anticholinergic side effects (dry mouth, constipation, urinary retention, orthostatic hypotension) limit use in elderly patients.
• Topical treatments: Capsaicin 8% patch (Qutenza — applied in-office, provides 3 months of relief by depleting substance P from nociceptors); topical lidocaine; compounded topical gabapentin/ketamine/baclofen formulations for localized pain.

Step 4: Advanced Modalities at Balance Foot & Ankle

• MLS (Multiwave Locked System) Laser Therapy: Class IV therapeutic laser delivering dual wavelengths (808 nm and 905 nm) simultaneously. Photobiomodulation reduces neuroinflammation, increases ATP production in damaged nerve mitochondria, stimulates nerve growth factor, and improves endoneurial blood flow. Patients typically receive 6–12 sessions. Studies demonstrate improved IENFD scores and reduced pain scores in DPN.
• Neuromodulation (peripheral nerve stimulation, TENS): Transcutaneous electrical nerve stimulation and spinal cord stimulation protocols modulate the dorsal horn pain gate, reducing centrally sensitized neuropathic pain.
• Custom orthotics and diabetic footwear: Redistribute plantar pressure away from insensate high-risk areas; accommodative orthoses with total-contact design prevent ulceration in neuropathic feet.

Most Common Mistakes

• Skipping the etiologic workup and going straight to Gabapentin: Up to 25% of peripheral neuropathy cases have a treatable cause (B12 deficiency, hypothyroidism, paraproteinemia). Prescribing symptomatic treatment without identifying and addressing the cause means the neuropathy will continue to progress despite medications.
• Ignoring foot protection in neuropathic patients: Loss of protective sensation makes injury invisible. Patients with confirmed neuropathy must be counseled never to walk barefoot, to inspect feet daily with a mirror, to wear properly fitted diabetic shoes, and to have their feet examined at every medical visit — not just by their podiatrist.

Red Flags — Seek Care Promptly

• Rapid or asymmetric progression: Neuropathy that develops or worsens over days to weeks, or that is clearly worse on one side, may represent an inflammatory, vasculitic, or compressive cause requiring urgent workup
• Prominent weakness: Foot drop or ascending weakness may indicate Guillain-Barré syndrome or CIDP — both potentially life-threatening if untreated
• Wound or ulcer found on neuropathic foot: Loss of protective sensation means ulcers may be present without pain — any wound on a neuropathic foot requires same-week evaluation
• Autonomic symptoms (dizziness on standing, loss of bladder/bowel control, inability to sweat): Autonomic neuropathy with cardiovascular involvement carries increased risk of silent cardiac ischemia and sudden death
• Saddle anesthesia or urinary retention: Suggests cauda equina involvement — spinal emergency requiring immediate imaging

Care at Balance Foot & Ankle

Our Bloomfield Hills and Howell offices provide comprehensive peripheral neuropathy evaluation and management for podiatric complications. We perform clinical neuropathy grading at every visit using validated tools, provide Semmes-Weinstein monofilament and vibratory testing, coordinate laboratory and NCS/EMG workup when indicated, and offer in-office MLS laser therapy for symptom management. Our focus is on three outcomes: halt progression, protect the insensate foot from injury, and reduce the burning pain that disrupts sleep and quality of life.

Call (810) 206-1402 or book online for a neuropathy evaluation. Same-week appointments are available at both locations.

Howell: 4330 E Grand River Ave, Howell MI 48843  |  Bloomfield Hills: 43494 Woodward Ave #208, Bloomfield Hills MI 48302